Recently obtained corporate documents show that Syngenta and its predecessor corporate entities had been discussing the safety of its Gramoxone paraquat-based products and suggest that the company resisted changes to the product formulation in an effort to protect profits, the Guardian reports.
Documents Show Syngenta Knew of Gramaxone Safety Issues
The CAMG Legal Marketing Index®. Significantly increase your marketing success, on us.
CAMG’s Legal Marketing Index® offers unprecedented reporting and comprehensive analysis of real-time data. Because more intelligent marketing decisions mean a better ROI.
